ライフサイエンスコーパス: CYP

1 CYP family genes differ in expression in whole tissue ho

2 CYP reactions in vivo require the cofactor NADPH as the

3 CYP reactions, therefore, are of high interest to the ph

4 CYP-001 (iPSC-derived MSCs) is produced using an optimiz

5 CYP-001 was safe and well tolerated.

6 CYP-13A12 promotes oxidation of polyunsaturated fatty ac

7 CYP-mediated stereoselective formation of diOH-PCBs from

8 CYPs (cytochrome p450) are critically involved in the me

9 chanism for mitochondrial import of family 1 CYPs but also reveal a direct role for mitochondrial CYP

10 tivation by cells expressing CYP1A1 and 2W1, CYPs known to be expressed in high frequency in some tum

11 be made for the promiscuous 2C9, 2D6 and 3A4 CYP isozymes, as well as CYPs 1A2, 2A6, 2B6, 2C8, 2C19 a

12 r acute heart failure, and cytochrome P-450 (CYP) 2C19 genotyping for the acute coronary syndromes.

13 rst to establish a biological activity for a CYP-produced metabolite of DGLA.

14 Cytochrome P450 (CYP)3A is the most abundant CYP enzyme in the human liver, and a functional impairme

15 ed secondary metabolites from chicory affect CYP expression and thereby might affect detoxification i

16 All CYP substrates and their metabolites were analyzed using

17 , encoding the single electron donor for all CYPs.

18 Using transgenic mice with altered CYP lipid biosynthetic pathways in a mouse model of lase

19 wo human steroidogenic enzymes, CYP 17A1 and CYP 19A1, that are major drug targets for cancer therapy

20 e with the combined inhibition of CYP 21 and CYP 17 enzymes.

21 t of the substrate classes of ADH, ALDH, and CYP.

22 Generation and analysis of key BACE1 and CYP 2D6 crystal structures identified strategies to obvi

23 cyte stability, rat free brain exposure, and CYP inhibition and induction liabilities.

24 r elucidate the likely metabolic pathway and CYP isoforms responsible for DHD1 and DHD3 production an

25 s, aqueous solubility, cell permeability and CYP inhibition, deeming it a suitable compound for in vi

26 equired metabotropic glutamate receptors and CYP omega-hydroxylase, the enzyme regulating 20-hydroxye

27 inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable f

28 oach to improve the microsomal stability and CYP inhibition profile of lead compounds 1a and 1b led t

29 es in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain p

30 observation of the unique pattern of TS and CYP assembly in eudicots and monocots.

31 ch of sequenced plant genomes for all TS and CYP genes reveals that distinct TS/CYP gene pairs are fo

32 by mixing and matching of individual TS and CYP genes through dynamic genome rearrangements.

33 ive pathway genes, transcription factors and CYPs related to camptothecin (CPT) biosynthesis.

34 to the selectivity toward IDO1 over TDO and CYPs.

35 emonstrate new functional pairing of TSs and CYPs within previously uncharacterized clusters.

36 SPR519 did not show any CYP or hERG liability.

37 us 2C9, 2D6 and 3A4 CYP isozymes, as well as CYPs 1A2, 2A6, 2B6, 2C8, 2C19 and 2E1.

38 cal studies of TxtC, an unusual bifunctional CYP involved in the biosynthesis of the EPA-approved her

39 in the physiological significance of bimodal CYP targeting to the endoplasmic reticulum and mitochond

40 interference studies demonstrated that both CYPs are promiscuous.

41 s and rodents in neocorticogenesis and brain CYP metabolism, translation of the research findings fro

42 ll of the relevant lipid species produced by CYP pathways.

43 ization of three novel compounds produced by CYP-mediated oxidation.

44 ive metabolism of chiral PCBs and OH-PCBs by CYPs is a major mechanism for atropisomer composition ch

45 rse spectrum of lipid nutrients regulated by CYPs, but also clearly indicate that the balance of thes

46 CYPminer completes CYP analyses for large-scale genomes from all kingdoms,

47 ion strategies that have been used to create CYP biosensors, with particular emphasis on mammalian dr

48 d gels remain robust strategies for creating CYP biosensors; however, the incorporation of novel mate

49 ll interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdow

50 ecreased in the bladder of cyclophosphamide (CYP)-treated mice, a commonly used model of bladder over

51 localized disease received cyclophosphamide (CYP) as part of the induction regimen.

52 g properties of MIP-QDs toward cypermethrin (CYP) are due to strong interactions between these molecu

53 ncluding pan-CYPomes (pan- and core-CYPome), CYP co-occurrence networks, CYP clouds, and genome clust

54 productive substrate binding among different CYP isoforms.

55 the assay was established for four different CYP model reactions, and the diagnostic concept was vali

56 rant cell growth via expression of different CYPs associated with estrogen metabolism and inflammatio

57 We identified several drosophila CYPs (dCYPs) whose knockdown reduced PCB 28-derived OH-m

58 The quest to create electroactive CYPs has led to many different immobilization strategies

59 In this study we found that C. elegans CYP-33E2 activity produces a range of epoxy and hydroxy

60 Screening with selective enzymatic CYP inhibitors identified CYP2A6 as the major isoform in

61 residues of two human steroidogenic enzymes, CYP 17A1 and CYP 19A1, that are major drug targets for c

62 le in the active site of the target enzymes, CYPs 51, from several pathogenic species.

63 Among 139 S. exigua CYPs, an ortholog (SE51385) to human EpOME synthase was

64 multicenter TRIUMPH study were genotyped for CYP polymorphisms.

65 c redox partner, cytochrome b5, required for CYP 17A1's lyase activity.

66 mpounds in drug development are screened for CYP activity.

67 nome annotation and comparative insights for CYPs.

68 Both loss-of-function and gain-of-function CYP polymorphisms affecting clopidogrel metabolism are a

69 pyrethroid resistance in Anopheles gambiae (CYPs 6M2, 6P3, 6P4, 6P5, 9J5, 9K1, 6Z2) and An. funestus

70 of two procedures i) to generate the Genome-CYP Matrix (GCM) that lists all occurrences of CYPs acro

71 proteases, which, in combination with a good CYP inhibition profile, suggested low off-target toxicit

72 nase 3 titers than patients who did not have CYP.

73 bition (IC50 > 50 muM) of a panel of hepatic CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, a

74 rd ERalpha and ERbeta, inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marm

75 = 422), CYP17, CYP19, and a panel of hepatic CYP enzymes.

76 f chicory root, on the expression of hepatic CYP mRNA (1A2, 2A19, 2C33, 2D25, 2E1 and 3A29), using pr

77 pounds with low metabolic stability and high CYP inhibition, whereas the protective effect of bromine

78 bility, and most are selective against human CYPs 1A2, 2D6, and 3A4 (<50% inhibition at 1 muM).

79 Recombinant human CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2

80 liver microsomes (HLM) and recombinant human CYPs, and to identify the CYP(s) that are active in the

81 The immobilized CYP can then act as a biosensor for the detection of CYP

82 However, immobilizing CYPs on an electrode can eliminate the need for NADPH an

83 Cytochrome P450 3A is the most important CYP subfamily in humans, and CYP3A4/CYP3A5 genetic varia

84 thiazole, along with analogues with improved CYP inhibition profile.

85 In CYP treated preparations SNAP also decreased by 33-55% B

86 d determination of individual alterations in CYP activity from human-derived liver samples in biopsy-

87 le to screening of individual differences in CYP enzyme function from biopsy-scale liver samples in a

88 the nitrogen can change regioselectivity in CYP metabolism.

89 m 79 +/- 15 spikes/s to 44 +/- 8 spikes/s in CYP pretreated but not untreated preparations.

90 The observed SNP-directed variation in CYP functionality indicated that vitamin D homeostasis i

91 the toxicity and drug interactions involving CYP enzymes.

92 iated with several cytochrome P450 isoforms (CYPs): 7-ethoxyresorufin-O-deethylase (EROD), benzyloxy-

93 We sought to identify key CYPs that could link drug or hormone metabolism to the d

94 llowing in vitro analysis using a liver-like CYP-cocktail, containing human orthologues of dCYP1A2, w

95 in the neutral OHCs, we suggest that a lower CYP-mediated metabolic activity can partially explain th

96 n and its BTPs, in vivo assays for measuring CYP activities, and G. pulex video-tracking suggested th

97 tivity of inhibitors against human metabolic CYP enzymes is presented.

98 issues in the context of lipid-metabolizing CYP enzymes, focusing particularly on the CYP450 family

99 ular emphasis on mammalian drug-metabolizing CYPs and characterization of CYP electrodes.

100 determination of the activity of microsomal CYP enzymes in a parallelized system at physiological te

101 Microsomal CYPs are anchored in the endoplasmic reticulum membrane

102 While the cytochrome P450 monooxygenases (CYP) from the CYP79 family forming aldoximes as biosynth

103 nthesized by cytochrome P450 monooxygenases (CYPs) and degraded by soluble epoxide hydrolase (sEH).

104 enzyme class cytochrome P450 monooxygenases (CYPs), thereby influencing the detoxification of co-occu

105 ification of cytochrome P450 monooxygenases (CYPs/P450s), great progress has been made in understandi

106 Cytochrome P450 monooxygenases (CYPs/P450s), heme thiolate proteins, are well known for

107 ults highlight the incorporation of multiple CYPs into diterpenoid metabolic engineering, and a conti

108 etylpyridinium, predicted to target nematode CYP-450 and HSP-90 respectively, were prioritized for in

109 nd core-CYPome), CYP co-occurrence networks, CYP clouds, and genome clustering data.

110 to date have investigated the association of CYP variants with outcomes in black patients.

111 Whereas the behavior of CYP 19A1 was rather insensitive to truncation of the TM-

112 ug-metabolizing CYPs and characterization of CYP electrodes.

113 then act as a biosensor for the detection of CYP activity with potential substrates, albeit only if t

114 It was devoid of CYP inhibition and was approximately 4000-fold selective

115 The effect of CYP polymorphisms on cardiovascular events among clopido

116 n the sex-based differences in expression of CYP family members and X-ist, which potentially leads to

117 f the TM-helix, mutations in the TM-helix of CYP 17A1, especially W2A and E3L, led to a gradual drift

118 r subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of either 1 x 1

119 n compatible with the combined inhibition of CYP 21 and CYP 17 enzymes.

120 n presented non-time-dependent inhibition of CYP activities in both human and rat liver.

121 c modeling, we showed that the inhibition of CYP-catalyzed biotransformation reactions indeed played

122 tigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a va

123 od bioavailability, high solubility, lack of CYP inhibition and low hepatotoxicity.

124 rom fish samples spiked with three levels of CYP.

125 ing foods remain to be evaluated in light of CYP pharmacogenetics.

126 derlying mechanism of cyt b(5) modulation of CYP catalysis.

127 successfully employed to detect residual of CYP in fish samples.

128 The role of CYP was assessed in human liver microsomes (HLM) and tyr

129 was to assess the safety and tolerability of CYP-001, while the secondary objectives were to evaluate

130 bolic engineering, and a continuing trend of CYP promiscuity generating complex networks in terpenoid

131 relapse, which may be related to less use of CYP in the induction regimen.

132 er voiding and restores the voided volume of CYP-treated mice.

133 facilitate rapid, comprehensive analysis of CYPs from genomes of all kingdoms.

134 However, functional characterization of CYPs has been challenging because of the expansive famil

135 In this study, we examined the effects of CYPs on the ligand responses of ORs in heterologous cell

136 t of the activity and coupling efficiency of CYPs using capillary electrophoresis with UV detection.

137 noamine oxidases shows minimal inhibition of CYPs and hERG and inhibits proliferation and survival in

138 different poplar parts via the inhibition of CYPs.

139 chers, such as a systematic investigation of CYPs across all kingdoms in terms of identification, cla

140 P Matrix (GCM) that lists all occurrences of CYPs across the genomes, and ii) to perform analyses and

141 associated with translational repression of CYPs.

142 o affect the expression of a distinct set of CYPs, including 1A1, 1A2, 2B6, 2C8, 3A4, and 7A1, but no

143 A subgroup of CYPs metabolize omega3-arachidonic and linoleic acids an

144 quently, any laboratory or industrial use of CYPs is limited by the need to supply NADPH and CPR.

145 d-type (WT), confirming strong reduction of (CYP-mediated) BS synthesis.

146 g interactions (DDI) were predicted based on CYP 2D6 affinities.

147 enum DS50662, a new cytochrome P450 (P450 or CYP) from Amycolatopsis orientalis (CYP105AS1) was isola

148 exhibited low off-target inhibition of other CYP isozymes.

149 YP2C8, making CYP2C8 distinct from the other CYP isoforms.

150 urbitacin core skeleton as well as two other CYPs responsible for the key structural variations among

151 enabled us to unveil a novel multi-oxidation CYP for the tailoring of the cucurbitacin core skeleton

152 we found that the cytochrome P450 oxygenase CYP-13A12 acts in response to the EGL-9-HIF-1 pathway to

153 rcumventing the time-dependent cytochrome P (CYP) 450 inhibition observed with the C6-CH(3)O prototyp

154 graft mice model, combination of P-DTX and P-CYP showed the most effective and persistent tumor growt

155 C-3 or RC-92a/hTERT prostate cancer cells, P-CYP preferentially kills and impairs the function of CD1

156 tes: HPMA copolymer-cyclopamine conjugate (P-CYP) preferentially toxic to cancer stem/progenitor cell

157 133+ cancer cells following combination or P-CYP treatments, indicating selective killing of cancer c

158 Cytochrome P450 (CYP) 1A1 is an extrahepatic monooxygenase involved in th

159 mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent antic

160 Cytochrome P450 (CYP) 1B1 is implicated in vascular smooth muscle cell mi

161 s primarily mediated by the cytochrome P450 (CYP) 26 enzymes, which play an essential role in control

162 metabolism by talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, increased the effects ofatRA

163 Previous studies implicate cytochrome P450 (CYP) 2B11 as an important clearance mechanism for these

164 evirapine is metabolized by cytochrome P450 (CYP) 2B6 and CYP3A4.

165 n mediated predominantly by cytochrome P450 (CYP) 2B6.

166 Human cytochrome P450 (CYP) 2C enzymes metabolize approximately 30% of clinical

167 ent confirmed inhibition of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, suggesting that durin

168 The degree to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of clopi

169 coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked

170 ied rifamycin induced DMEs, cytochrome P450 (CYP) 2C8/3A4/3A5, SULT2A, and UGT1A4/1A5 and predicted l

171 elective inhibitor of human cytochrome P450 (CYP) 2C9 isozyme, was identified as a novel and leading

172 /mutagenic intermediates by cytochrome p450 (CYP) 2D6 and CYP2E1 enzymes.

173 n the vascular endothelium, cytochrome P450 (CYP) 2J2 is one of the CYP epoxygenases that metabolize

174 diabetes suppressed hepatic cytochrome P450 (CYP) 2R1, the main vitamin D 25-hydroxylase responsible

175 Cytochrome P450 (CYP) 3A accounts for nearly 30% of the total CYP enzymes

176 d that dronedarone inhibits cytochrome P450 (CYP) 3A4 and 3A5 in a time-dependent manner.

177 ts tacrolimus metabolism by cytochrome P450 (CYP) 3A4 and could lead to tacrolimus overexposure in pa

178 Cytochrome P450 (CYP) 3A4 is a major contributor to hepatic drug and xeno

179 Cytochrome P450 (CYP) 4A and 4F enzymes metabolize arachidonic acid to 20

180 n to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche formation a

181 f indole-3-acetic acid, and Cytochrome P450 (CYP) 71B6 were found to be transcriptionally coexpressed

182 nyls (PCBs) is initiated by cytochrome P450 (CYP) enzymes and includes PCB oxidation to OH-metabolite

183 interactions with catabolic cytochrome P450 (CYP) enzymes can inhibit chemical elimination pathways a

184 The human cytochrome P450 (CYP) enzymes CYP3A4 and CYP3A5 metabolize most drugs and

185 acid epoxides generated by cytochrome P450 (CYP) enzymes have been linked to increased tumor growth

186 l role of drug metabolizing cytochrome P450 (CYP) enzymes in human plasma exosomes are yet to be expl

187 The superfamily of hepatic cytochrome P450 (CYP) enzymes is responsible for the intrinsic clearance

188 Human cytochrome P450 (CYP) enzymes play an important role in the metabolism of

189 Mtb H37Rv strain encodes 20 cytochrome P450 (CYP) enzymes, many of which are implicated in Mtb surviv

190 sEH limits tissue levels of cytochrome P450 (CYP) epoxides derived from omega-6 and omega-3 polyunsat

191 between endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.

192 Cytochrome P450 (CYP) epoxygenases generate bioactive lipid epoxides whic

193 ed from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain car

194 yl side chain by enzymes of cytochrome P450 (CYP) families 125 and 142.

195 Cytochrome P450 (CYP) family members are known to be present in the olfac

196 ate synthetase1 and several cytochrome P450 (CYP) genes in this culture system.

197 , the expression of several cytochrome P450 (CYP) genes were also modified in both fungi by MP4, whic

198 TRZ) is unrepresented among cytochrome P450 (CYP) inhibitors.

199 nsport in humans, including cytochrome P450 (CYP) isoform 7A1 (CYP7A1), CYP27A1, CYP8B1, uridine 5'-d

200 atty acids derived from the cytochrome P450 (CYP) monooxygenase pathway serve as vital second messeng

201 h hepatic disruption of the cytochrome p450 (CYP) oxidoreductase gene, encoding the single electron d

202 rt related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism.

203 hesis that enzymes from the cytochrome P450 (CYP) superfamily can participate in the catalysis of non

204 st all known members of the cytochrome P450 (CYP) superfamily conserve a key cysteine residue that co

205 of Phase I and II enzymes (cytochrome P450 (CYP), uridine glucuronic acid transferase (UGT), and sul

206 derived from discoidol via cytochrome P450 (CYP)-catalyzed oxidative cleavage.

207 e investigated the roles of cytochrome P450 (CYP)-derived epoxy-oxylipins in a well-characterized mod

208 Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data

209 t predicts isozyme-specific cytochrome P450 (CYP)-mediated sites of metabolism (SOMs) on drug-like mo

210 The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film o

211 OX), lipoxygenase (LOX), or cytochrome P450 (CYP).

212 se (BIS), is catalyzed by a cytochrome P450 (CYP).

213 Cytochrome P450 (CYP)1A enzymes are protective against hyperoxic lung inj

214 (TCDD) on the expression of cytochrome P450 (CYP)1A1 and cytokines in various tissues of mice.

215 Mutations in the cytochrome p450 (CYP)21A2 gene, which encodes the enzyme steroid 21-hydro

216 Cytochrome P450 (CYP)2C9 and CYP2C19 are important human enzymes that met

217 sent in 8 sera; 11 had anti-cytochrome P450 (CYP)2E1 Abs, 14 had Abs against CYP2E1 modified by INH,

218 Cytochrome P450 (CYP)3A is the most abundant CYP enzyme in the human live

219 thylation for X-ist and for cytochrome P450 (CYP; family members 1a1, 2e1m, and 7b1.

220 Genes encoding cytochrome P450 (CYP; P450) enzymes occur widely in the Archaea, Bacteria

221 to various membrane-bound cytochromes P450 (CYPs) and their electron transferring protein partners,

222 Cytochromes P450 (CYPs) are potential enzymes responsible for hydroxylatio

223 Cytochromes P450 (CYPs) catalyze various oxidative transformations in drug

224 Cytochromes P450 (CYPs) play a key role in generating the structural diver

225 e scaffold diversity), and cytochromes P450 (CYPs), which modify and further diversify these scaffold

226 e for drug metabolism (i.e. cytochrome P450 [CYP] 3A4, CYP1A2).

227 Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid metabolism, c

228 Cytochrome P450 (P450, CYP) 21A2 is the major steroid 21-hydroxylase, convertin

229 Cytochrome P450 (P450, CYP) enzymes are the major catalysts involved in the oxi

230 Cytochromes P450 (P450, CYP) metabolize a wide variety of endogenous and exogeno

231 pharmacokinetic relevance (cytochrome P450; CYP).

232 up-regulated genes include cytochrome P450s (CYP) CYP6P9a, CYP6P9b and CYP6M7.

233 Cytochrome P450s (CYPs) are a large family of heme-containing monooxygenas

234 Cytochrome P450s (CYPs) are functionally diverse monooxygenases responsibl

235 tudies have indicated that cytochrome P450s (CYPs) are involved in the metabolism of polybrominated d

236 osine hydroxylase (TH) and cytochrome P450s (CYPs) catalyzed this process.

237 Characterization of the cytochrome P450s (CYPs) identified from these loci enabled us to unveil a

238 m of SlMIXTA-like included cytochrome P450s (CYPs) of the CYP77A and CYP86A subfamilies, LONG-CHAIN A

239 The cytochrome P450s (CYPs) represent a highly divergent class of enzymes invo

240 the UK for use in children and young people (CYP) or included in national guidelines.

241 he creation of highly sensitive and portable CYP biosensors.

242 ependent nonlinear PK and is likely a potent CYP 3A inhibitor.

243 CYP2B6 was the predominant CYP capable of forming six OH-BDEs, including 3-OH-BDE-4

244 Patients who received CYP during induction had significantly (P = 0.027) lower

245 ubject in cohort B withdrew before receiving CYP-001 and was excluded from analysis.

246 in enhanced metabolic stability and reduced CYP inhibition.

247 This translated into significantly reduced CYP 3A4 induction for compounds 71 and 73.

248 Thus we silenced selected CYPs via RNA interference and analyzed the effect on PCB

249 to coding and regulatory variants at several CYP* and UGT* genes as well as corroborative evidence fo

250 showed no significant inhibition of several CYPs, demonstrated efficient RBC partitioning and high m

251 all induced increased expression of specific CYPs, while esculin showed no effect.

252 ance of selectivity over other steroidogenic CYP enzymes, in particular 11beta-hydroxylase (CYP11B1),

253 ew class of P2X4 inhibitors with substantial CYP 3A4 induction in human hepatocytes.

254 to OH-PCB3s in whole poplars because suicide CYP inhibitors ABT and ODYA both led to sharp decreases

255 Cytochrome P450 monooxygenases (termed CYPs or P450s) are hemoproteins ubiquitously found acros

256 All results pointed to the conclusion that CYP enzymes were the agents which metabolized PCB3 to OH

257 We show that CYP enzymes can metabolize multiple sterols in vitro, es

258 These results suggest that CYP lipid signaling molecules and their regulators are p

259 environmental exposure, we hypothesize that CYPs play a role in the development and maintenance of p

260 ix is unclear because it has been shown that CYPs can still associate with the membrane and have enzy

261 The CYP activities are determined with the help of prefluore

262 The CYP subfamily 2J polypeptide 2 (CYP2J2) was upregulated

263 amptic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propyn

264 ydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.

265 recombinant human CYPs, and to identify the CYP(s) that are active in the oxidative metabolism of BD

266 influenced the membrane interactions of the CYP 17A1 globular domain.

267 ium, cytochrome P450 (CYP) 2J2 is one of the CYP epoxygenases that metabolize arachidonic acid to pro

268 and may be relevant to other members of the CYP family of biologic, medical, and pharmacological imp

269 death of photoreceptors and suggest that the CYP monooxygenase system is a risk factor for retinal ph

270 We discovered that the CYP-derived lipid metabolites epoxydocosapentaenoic acid

271 trate access tunnel from the membrane to the CYP active site, indicating a possible effect on enzyme

272 Eicosanoids derived from AA via the CYP and LOX biosynthetic pathways were positively associ

273 Among the CYPs tested, co-expression of CYP1a2 significantly affec

274 l-atom molecular dynamics simulations of the CYPs in a phospholipid bilayer.

275 ive miRNA binding sites on the 3'UTRs of the CYPs were identified in-silico.

276 tigate their synergistic potential and their CYP inhibition strength in the aquatic invertebrate Gamm

277 t, when we promoted the degradation of these CYP-derived metabolites by transgenic overexpression of

278 ow starting to discern the patterns of these CYP-PUFA products in health and disease.

279 These CYPs had similar transcription profiles to that of the k

280 therapeutic index drugs metabolized by these CYPs require close monitoring.

281 reover, we demonstrated the utility of these CYPs by engineering yeast for heterologous production of

282 zation of the WT CYP105AS1 reveals that this CYP is an efficient compactin hydroxylase, but that pred

283 s adverse events were assessed as related to CYP-001.

284 ophila and the human systems with respect to CYP mediated metabolism and PCB mediated neurotoxicity.

285 derstanding of the azole binding not only to CYPs 51 from the pathogenic species but also to differen

286 CYP) 3A accounts for nearly 30% of the total CYP enzymes in the human liver and participates in the m

287 d be expected by chance, and that certain TS/CYP pairings predominate, providing signals for key even

288 ll TS and CYP genes reveals that distinct TS/CYP gene pairs are found together far more commonly than

289 s; in the former, microsyntenic blocks of TS/CYP gene pairs duplicate and provide templates for the e

290 We recover TS/CYP gene pairs for previously characterized terpene meta

291 Therefore, two CYP suicide inhibitors, 1-aminobenzotriazole (ABT) and 1

292 Here we present the characterization of two CYPs, CYP76AH3 and CYP76AK1, which act sequentially to f

293 clotrimazole-bound AcCYP51 adopted a typical CYP monomer structure, isavuconazole-bound AcCYP51 faile

294 Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibit

295 Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV)

296 However, the kinetics of drug clearance via CYPs varies significantly among individuals due to both

297 all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved

298 hermore, they display fewer liabilities with CYP-metabolizing enzymes and hERG compared with ispinesi

299 his method showed a linear relationship with CYP concentration over the range of 0.05-60.0 mg/kg with

300 excitability and urothelial ATP release with CYP-induced cystitis is decreased with TGF-beta inhibiti